Loading stock data…
$1.44+0.05 (+3.60%)
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
Cellectar Biosciences, Inc. in the Healthcare sector is trading at $1.44 with a market capitalization of $22M. Wall Street consensus targets $11.50 (4 analysts), implying a +698.6% move over the next 12 months. The stock is currently near its 52-week low of $1.34, remaining 47.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.20M↓ | -$5.79M↓ | -$5.69M↓ | -$4.85M↑ | -$6.04M |
| Net Income | -$6.93M↓ | -$5.65M↓ | -$5.30M↓ | -$4.44M↑ | -$5.45M |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate ...